{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'exploration of the AR-signaling axis as a therapeutic target in men with CRPC.', 'Subsequently, newer AR-directed agents like abiraterone and enzalutamide, which', 'inhibit AR-signaling in men with CRPC through disrupting the ligand-AR interaction (Abi', 'through ligand depletion and Enza through receptor antagonism) have been', 'developed. 19-23 The next-generation pure AR-antagonist apalutamide builds on the', 'success of enzalutamide, with improved pharmacokinetics/pharmacodynamic', '(PK/PD), and is currently under clinical investigation. 24', 'Given the proven track record of targeting the androgen/AR axis in the more', 'advanced setting, AR-signaling inhibitors are the logical choice to evaluate at an earlier', 'stage. Indeed, twenty-four weeks of neoadjuvant abiraterone acetate in combination', 'with an LHRH agonist (leuprolide) has been reported to result in a 24% total/near total', 'pathologic complete response (pCR) rate as documented in prostatectomy', 'specimens.25 Monotherapy with apalutamide may have the theoretical advantage of not', 'causing prolonged testosterone suppression. This is in contrast to the LHRH agonists', 'which have been documented to cause prolonged testosterone suppression following', 'their discontinuation. 26-29', 'The hypothesis of this trial is that apalutamide will lead to negative repeat', 'biopsies as determined through systematic and site directed biopsies in active', 'surveillance patients, which should in turn lead to decreased rates of pathologic', 'progression and attrition from active surveillance.', '1.2. Androgen/Androgen Receptor Directed Therapies', 'The initial management of advanced prostate cancer, as well as higher risk', 'localized prostate cancer being treated with radiation therapy, typically involves', 'targeting the androgen/androgen receptor (AR) signaling axis through lowering serum', 'testosterone levels. 16,30 This is accomplished either through surgical castration or now', 'more commonly with an LHRH agonist/antagonist (i.e., hormonal therapy [HT]).', 'Hormonal therapy is initially highly effective in those with metastatic prostate cancer,', 'leading to objective responses in >85% of individuals.17 Unfortunately, after a variable', 'period of symptom relief, androgen ablation invariably ceases to suppress prostate', 'cancer growth and patients eventually succumb to their disease. This disease state', 'defined by progression in spite of androgen ablation has been termed castrate resistant', '11', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'prostate cancer (CRPC). 18 More recently it has come to light that CRPC is still largely', 'dependent on androgen/AR axis signaling. This realization has led to the development', 'of', 'multiple newer AR directed therapies. 19-23 Mechanistically these agents primarily', 'work either through ligand depletion (e.g., abiraterone acetate) or through interference', 'with AR trafficking and signaling (e.g., apalutamide, enzalutamide).', 'Traditional HTs have several unwanted side effects, making their use in an', 'otherwise healthy population of men somewhat disadvantageous. Specifically, these', \"agents have been shown to increase one's risk of diabetes and cardiovascular disease,\", 'lead to weight gain, and cause serum total cholesterol levels to increase. 31-34 While one', 'could argue that brief periods of LHRH agonist therapy are unlikely to produce such', 'unwanted effects, it has been well documented that the use of HT for even a transient', 'period of time can lead to prolonged periods of testosterone suppression - potentially', 'putting these men at risk for the aforementioned side effects. 26-29 After approximately 8', 'months of HT only ~35% of men will recover their testosterone to baseline and only 70-', '80% of men will recover their testosterone to within a normal range. 35', '1.2.1. APALUTAMIDE', 'Apalutamide works through competitive AR inhibition and unlike the older', 'anti-androgens (e.g., bicalutamide, nilutamide), is a pure AR antagonist. It', 'additionally has the ability to prevent AR nuclear translocation and DNA binding', 'to nuclear response elements.24 It is generally felt to function similarly to', 'enzalutamide, another AR targeted therapy approved for men with mCRPC pre-', 'and post-docetaxel. In docetaxel pre-treated patients enzalutamide was shown to', 'result in a 37% reduced risk of death compared to placebo (HR 0.63, 95% CI,', '0.53-0.75; P<0.001), and in docetaxel na\u00efve patients it led to a 29% reduction in', 'the risk of death compared to placebo (HR 0.71, 95% CI, 0.60 to 0.84;', 'P<0.001). 22,23 Preclinical work comparing apalutamide to enzalutamide,', 'however, demonstrated that apalutamide may have several theoretical', 'advantages over enzalutamide.36 Namely, in mouse models apalutamide was', 'able to achieve a maximal therapeutic effect at 30 mg/kg/day compared to 100', 'mg/kg/day of enzalutamide (Figure 1). Apalutamide is also able to achieve', 'equivalent intra-tumoral concentrations at a lower plasma steady state', 'concentration compared to enzalutamide. Finally, while high-dose Apalutamide', '12', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}